Disclosed are methods for diagnosing Lyme disease and distinguishing a new infection from a persistent infection of Borrelia burgdorferi in a subject.

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.

Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible for the effect.

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

The present invention relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The present invention also relates to methods and apparati for obtaining single cells that express immune binding proteins. The single cells expressing the immune binding proteins can be obtained from a patient that has had an effective immune response to a disease state (e.g., cancer or an infectious agent). The methods and apparati of the disclosure can be used to obtain immune cells that produce immune binding proteins responsible for the effective immune response. The methods and apparati of the disclosure can also be used to obtain cells that express a polypeptide (e.g., a receptor, a secreted protein, a cytokine, or a recombinant protein) or other factor of interest.

A 3D microfluidic device for use as an in vitro lymph node is described. The microfluidic device has a body with a semi-circular inner wall and a first channel located adjacent along the semi-circular inner wall, the first channel corresponding to a subcapsular sinus region of a lymph node, a second channel located adjacent the first channel, the second channel corresponding to a reticular network, and a bottom cavity and top cavity, centrally located, corresponding to a paracortex and follicle of a lymph node, respectively. The various compartments of the device are separated by circumferentially and horizontally located rows of micro-pillars. A lab-on-a-chip device incorporating the microfluidic device is also described.

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.